Download PDF
Thromb Haemost 2024; 124(04): 351-362
DOI: 10.1055/a-2188-8773
Coagulation and Fibrinolysis

Risk Factors for Bleeding in Cancer Patients Treated with Conventional Dose Followed by Low-Dose Apixaban for Venous Thromboembolism

Parwana Hussaini
1   The Medical Student Research Program, Faculty of Medicine, University of Oslo, Oslo, Norway
,
Trine-Lise Larsen
2   Department of Hematology, Akershus University Hospital, Lørenskog, Norway
3   Institute of Clinical Medicine, University of Oslo, Oslo, Norway
,
Waleed Ghanima
3   Institute of Clinical Medicine, University of Oslo, Oslo, Norway
4   Clinic of Internal Medicine, Østfold Hospital, Grålum, Norway
,
Anders Erik Astrup Dahm
2   Department of Hematology, Akershus University Hospital, Lørenskog, Norway
3   Institute of Clinical Medicine, University of Oslo, Oslo, Norway
› Author Affiliations
Funding The study was funded by grants from the Norwegian South-Eastern Health Authority (Grant number 243861), Akershus University Hospital (Grant number 296910), Pfizer Norway, and the Norwegian Research Council (Grant number 271555/F20).
› Further Information
Also available at
   Permissions and Reprints


Abstract

Background Incidence of and risk factors for bleeding in cancer patients with venous thromboembolism (VTE) treated with apixaban are poorly described.

Methods We analyzed data from the prospective CAP study where 298 cancer patients with any type of VTE received 5 mg apixaban twice daily for 6 months, and then 2.5 mg apixaban twice daily for 30 months. For most analyses, major bleedings and clinically relevant nonmajor bleedings were merged to “clinically relevant bleedings.” Risk factors were estimated by odds ratios (OR) and 95% confidence intervals (CIs).

Results The incidence of clinically relevant bleedings was 38% per person-year during the first 6 months of treatment, 21% per person-year from 7 to 12 months, and between 4 and 8% per person-year from 13 to 36 months. Clinically relevant bleedings were associated with age above 74 years (OR: 2.0, 95% CI: 1.0–4.1), body mass index (BMI) below 21.7 (OR: 2.3, 95% CI: 1.1–4.8), and hemoglobin at baseline below 10.5 for females (OR: 2.8, 95% CI: 1.1–7.3) and 11.1 for males (OR: 3.3, 95% CI: 1.3–8.4) during the first 6 months. Gastrointestinal (GI) or urogenital cancer was not associated with clinically relevant bleedings compared with other cancers. Among patients with luminal GI cancer, nonresected cancer had increased risk of bleeding (OR: 3.4, 95% CI: 1.0–11.6) compared with resected GI cancer.

Conclusion There were very few bleedings while patients were on low-dose apixaban. Factors associated with bleeding in patients treated with full-dose apixaban were high age, low BMI, and low hemoglobin, and probably nonresected luminal GI cancer.

Keywords

anticoagulant - apixaban - cancer - venous thromboembolism - risk factors for bleeding

Supplementary Material



Publication History

Received: 11 June 2023

Accepted: 09 October 2023

Accepted Manuscript online:
10 October 2023

Article published online:
15 November 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5 (04) 692-699
    CrossrefPubMedSearch in Google Scholar
  • 2 Flinterman LE, van Hylckama Vlieg A, Cannegieter SC, Rosendaal FR. Long-term survival in a large cohort of patients with venous thrombosis: incidence and predictors. PLoS Med 2012; 9 (01) e1001155-e1001155
    CrossrefPubMedSearch in Google Scholar
  • 3 Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160 (06) 809-815
    CrossrefPubMedSearch in Google Scholar
  • 4 Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293 (06) 715-722
    CrossrefPubMedSearch in Google Scholar
  • 5 Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 2007; 5 (Suppl. 01) 246-254
    CrossrefPubMedSearch in Google Scholar
  • 6 Prandoni P, Lensing AWA, Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
    CrossrefPubMedSearch in Google Scholar
  • 7 David Green HCK. Coagulation in Cancer. New York, NY: Springer US; 2009
    Search in Google Scholar
  • 8 Peterson DE, Cariello A. Mucosal damage: a major risk factor for severe complications after cytotoxic therapy. Semin Oncol 2004; 31 (3, Suppl 8): 35-44
    CrossrefPubMedSearch in Google Scholar
  • 9 McBane II RD, Wysokinski WE, Le-Rademacher JG. et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 2020; 18 (02) 411-421
    CrossrefPubMedSearch in Google Scholar
  • 10 Young AM, Marshall A, Thirlwall J. et al. Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36 (20) 2017-2023
    CrossrefPubMedSearch in Google Scholar
  • 11 Agnelli G, Becattini C, Meyer G. et al; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17) 1599-1607
    CrossrefPubMedSearch in Google Scholar
  • 12 Raskob GE, van Es N, Verhamme P. et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
    CrossrefPubMedSearch in Google Scholar
  • 13 Riaz IB, Fuentes HE, Naqvi SAA. et al. Direct oral anticoagulants compared with dalteparin for treatment of cancer-associated thrombosis: a living, interactive systematic review and network meta-analysis. Mayo Clin Proc 2022; 97 (02) 308-324
    CrossrefPubMedSearch in Google Scholar
  • 14 Giustozzi M, Agnelli G, Del Toro-Cervera J. et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis. Thromb Haemost 2020; 120 (07) 1128-1136
    Thieme ConnectPubMedSearch in Google Scholar
  • 15 Ageno W, Vedovati MC, Cohen A. et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study. Thromb Haemost 2021; 121 (05) 616-624
    Thieme ConnectPubMedSearch in Google Scholar
  • 16 Kraaijpoel N, Di Nisio M, Mulder FI. et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE cancer study. Thromb Haemost 2018; 118 (08) 1439-1449
    Thieme ConnectPubMedSearch in Google Scholar
  • 17 Mulder FI, Bosch FTM, Young AM. et al. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood 2020; 136 (12) 1433-1441
    CrossrefPubMedSearch in Google Scholar
  • 18 Agnelli G, Muñoz A, Franco L. et al. Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thromb Haemost 2022; 122 (05) 796-807
    Thieme ConnectPubMedSearch in Google Scholar
  • 19 Hannevik T-L, Brekke J, Enden T. et al. Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism. Thromb Res 2020; 196: 238-244
    CrossrefPubMedSearch in Google Scholar
  • 20 Larsen TL, Garresori H, Brekke J. et al. Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up. J Thromb Haemost 2022; 20 (05) 1166-1181
    CrossrefPubMedSearch in Google Scholar
  • 21 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
    CrossrefPubMedSearch in Google Scholar
  • 22 Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13 (11) 2119-2126
    Search in Google Scholar
  • 23 Ruíz-Giménez N, Suárez C, González R. et al; RIETE Investigators, Findings from the RIETE Registry. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Thromb Haemost 2008; 100 (01) 26-31
    Thieme ConnectPubMedSearch in Google Scholar
  • 24 Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138 (05) 1093-1100
    CrossrefPubMedSearch in Google Scholar
  • 25 Klok FA, Barco S, Turpie AGG. et al. Predictive value of venous thromboembolism (VTE)-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with VTE: results of the XALIA study. Br J Haematol 2018; 183 (03) 457-465
    CrossrefPubMedSearch in Google Scholar
  • 26 Weitz JI, Farjat AE, Ageno W. et al; GARFIELD-VTE Investigators. Influence of body mass index on clinical outcomes in venous thromboembolism: insights from GARFIELD-VTE. J Thromb Haemost 2021; 19 (12) 3031-3043
    CrossrefPubMedSearch in Google Scholar
  • 27 Vicente-Ibarra N, Marín F, Pernías-Escrig V. et al. Impact of anemia as risk factor for major bleeding and mortality in patients with acute coronary syndrome. Eur J Intern Med 2019; 61: 48-53
    CrossrefPubMedSearch in Google Scholar
  • 28 van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briët E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993; 153 (13) 1557-1562
    CrossrefPubMedSearch in Google Scholar
  • 29 Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The National Consortium of Anticoagulation Clinics. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996; 124 (11) 970-979
    CrossrefPubMedSearch in Google Scholar
  • 30 Fang MC, Chang Y, Hylek EM. et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004; 141 (10) 745-752
    CrossrefPubMedSearch in Google Scholar
  • 31 Bosch FTM, Mulder FI, Huisman MV. et al. Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. J Thromb Haemost 2021; 19 (12) 3008-3017
    CrossrefPubMedSearch in Google Scholar
  • 32 Vedovati MC, Giustozzi M, Munoz A. et al. Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism. Eur J Intern Med 2023; 112: 29-36
    CrossrefPubMedSearch in Google Scholar
  • 33 de Winter MA, Dorresteijn JAN, Ageno W. et al. Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score. Thromb Haemost 2022; 122 (05) 818-829
    Thieme ConnectPubMedSearch in Google Scholar
  • 34 Houghton DE, Vlazny DT, Casanegra AI. et al. Bleeding in patients with gastrointestinal cancer compared with nongastrointestinal cancer treated with apixaban, rivaroxaban, or enoxaparin for acute venous thromboembolism. Mayo Clin Proc 2021; 96 (11) 2793-2805
    CrossrefPubMedSearch in Google Scholar